产品
编 号：F747258
分子式：C14H14N6O2
分子量：298.3
分子式：C14H14N6O2
分子量：298.3
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1809420-71-0
产品详情
生物活性：
Resomelagon (AP1189) is a potent, orally active melanocortin receptor (MR) agonist about MC1 and MC3. Resomelagon induces ERK1/2 phosphorylation and Ca2+ mobilization. Resomelagon has anti-inflammatory activity. Resomelagon can be used for obesity and chronic inflammation research.
体内研究：
Resomelagon（0-10 mg/kg；腹腔注射、静脉注射、口服.；24 小时；雄性 C57BL/6J 野生型 (WT) 和 BALB/c 小鼠）促进体内急性炎症的消退[1 ]。Resomelagon（25-50 mg/kg；口服；每日一次，持续 8 天；雄性 C57BL/6J 野生型 (WT) 和 BALB/c 小鼠）减少小鼠的关节炎。Animal Model:Male C57BL/6J wild-type (WT) and BALB/c mice
Dosage:0, 0.1, 1 and 10 mg/kg
Administration:Oral administration, intraperitoneal injection and intravenous injection; for 24 hours
Result:Inhibited neutrophil and monocyte infiltration in a dose-dependent manner.
Animal Model:Male C57BL/6J wild-type (WT) and BALB/c mice
Dosage:25 and 50 mg/kg
Administration:Oral administration; daily; for 8 days
Result:Reduced all signs of arthritis measured, including clinical score (-42%), paw swelling (-87%), proportion of animals with all four paws affected (-50%), and the severity of the inflammation (-70%).
体外研究：
Resomelagon（0-1000 μM；8 分钟；HEK293A 细胞）通过 ERK1/2 磷酸化和 Ca2+ 动员促进黑皮质素信号转导 。Resomelagon（1 nM；30 分钟；腹膜巨噬细胞）具有抗炎活性并抑制 TNF-α 释放和胞吐作用。
Resomelagon (AP1189) is a potent, orally active melanocortin receptor (MR) agonist about MC1 and MC3. Resomelagon induces ERK1/2 phosphorylation and Ca2+ mobilization. Resomelagon has anti-inflammatory activity. Resomelagon can be used for obesity and chronic inflammation research.
体内研究：
Resomelagon（0-10 mg/kg；腹腔注射、静脉注射、口服.；24 小时；雄性 C57BL/6J 野生型 (WT) 和 BALB/c 小鼠）促进体内急性炎症的消退[1 ]。Resomelagon（25-50 mg/kg；口服；每日一次，持续 8 天；雄性 C57BL/6J 野生型 (WT) 和 BALB/c 小鼠）减少小鼠的关节炎。Animal Model:Male C57BL/6J wild-type (WT) and BALB/c mice
Dosage:0, 0.1, 1 and 10 mg/kg
Administration:Oral administration, intraperitoneal injection and intravenous injection; for 24 hours
Result:Inhibited neutrophil and monocyte infiltration in a dose-dependent manner.
Animal Model:Male C57BL/6J wild-type (WT) and BALB/c mice
Dosage:25 and 50 mg/kg
Administration:Oral administration; daily; for 8 days
Result:Reduced all signs of arthritis measured, including clinical score (-42%), paw swelling (-87%), proportion of animals with all four paws affected (-50%), and the severity of the inflammation (-70%).
体外研究：
Resomelagon（0-1000 μM；8 分钟；HEK293A 细胞）通过 ERK1/2 磷酸化和 Ca2+ 动员促进黑皮质素信号转导 。Resomelagon（1 nM；30 分钟；腹膜巨噬细胞）具有抗炎活性并抑制 TNF-α 释放和胞吐作用。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备